Pax I-Bio Tech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 24 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -48.93%
(FY 2021)
- Profit -9672.02%
(FY 2021)
- Ebitda -10315.90%
(FY 2021)
- Net Worth -411.41%
(FY 2021)
- Total Assets -45.15%
(FY 2021)
About Pax I-Bio Tech
The Corporate was formerly known as Pax Infotech Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Xerxes Batliwala, Rajshree Pathare, and Shreyas Pathare serve as directors at the Company.
- CIN/LLPIN
U74110MH2000PTC129300
- Company No.
129300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2000
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pax I-Bio Tech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Xerxes Batliwala  | Director | 20-Oct-2000 | Current |
Rajshree Pathare  | Additional Director | 01-Jan-2018 | Current |
| Shreyas Pathare | Director | 20-Oct-2000 | Current |
Financial Performance and Corporate Structure Insights of Pax I-Bio Tech.
Pax I-Bio Tech Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 48.93% decrease. The company also saw a substantial fall in profitability, with a 9672.02% decrease in profit. The company's net worth observed a substantial decline by a decrease of 411.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pax I-Bio Tech?
In 2021, Pax I-Bio Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Pax Polysynth Private LimitedActive 44 years 5 months
Xerxes Batliwala and Shreyas Pathare are mutual person
- Pax Enterprise Private LimitedActive 27 years 10 months
Xerxes Batliwala and Shreyas Pathare are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pax I-Bio Tech?
Unlock and access historical data on people associated with Pax I-Bio Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pax I-Bio Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pax I-Bio Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
